{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:37:10Z","timestamp":1792712230431,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["202103021224419"],"award-info":[{"award-number":["202103021224419"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115125","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T08:39:55Z","timestamp":1688632795000},"page":"115125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1\/HIF-1\u03b1 signaling pathway"],"prefix":"10.1016","volume":"165","author":[{"given":"Jingyao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.biopha.2023.115125_bib1","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1161\/CIRCULATIONAHA.111.087726","article-title":"Global cardiovascular health promotion and disease prevention: 2011 and beyond","volume":"125","author":"Labarthe","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.biopha.2023.115125_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cvr\/cvu013","article-title":"Pregnancy as a cardiac stress model","volume":"101","author":"Chung","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib4","first-page":"5","article-title":"Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms","volume":"98","author":"Ellison","year":"2012","journal-title":"Heart (Br. Card. Soc. )"},{"issue":"8","key":"10.1016\/j.biopha.2023.115125_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrm1983","article-title":"Regulation of cardiac hypertrophy by intracellular signalling pathways","volume":"7","author":"Heineke","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"17","key":"10.1016\/j.biopha.2023.115125_bib6","doi-asserted-by":"crossref","first-page":"85i","DOI":"10.1016\/0002-9149(87)90466-8","article-title":"Population implications of electrocardiographic left ventricular hypertrophy","volume":"60","author":"Kannel","year":"1987","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115125_bib7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1423-0127-19-102","article-title":"Hypoxia-regulated target genes implicated in tumor metastasis","volume":"19","author":"Tsai","year":"2012","journal-title":"J. Biomed. Sci."},{"issue":"4 Suppl","key":"10.1016\/j.biopha.2023.115125_bib9","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","article-title":"HIF-1 and tumor progression: pathophysiology and therapeutics","volume":"8","author":"Semenza","year":"2002","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2023.115125_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2009.05.005","article-title":"Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy","volume":"9","author":"Krishnan","year":"2009","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.biopha.2023.115125_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.118.10845","article-title":"Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1\u03b1 Mechanisms","volume":"72","author":"Kumar","year":"2018","journal-title":"Hypertens. (Dallas, Tex: 1979)"},{"issue":"10","key":"10.1016\/j.biopha.2023.115125_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.467","article-title":"miR-181a increases FoxO1 acetylation and promotes granulosa cell apoptosis via SIRT1 downregulation","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell death Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115125_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41556-020-00579-5","article-title":"SIRT1 is downregulated by autophagy in senescence and ageing","volume":"22","author":"Xu","year":"2020","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115125_bib14","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1038\/s41418-021-00821-z","article-title":"SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis","volume":"28","author":"Leng","year":"2021","journal-title":"Cell death Differ."},{"issue":"2","key":"10.1016\/j.biopha.2023.115125_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12904","article-title":"Sirt1-hypoxia-inducible factor-1\u03b1 interaction is a key mediator of tubulointerstitial damage in the aged kidney","volume":"18","author":"Ryu","year":"2019","journal-title":"Aging Cell"},{"issue":"16","key":"10.1016\/j.biopha.2023.115125_bib16","first-page":"2018","article-title":"SIRT1 relieves Necrotizing Enterocolitis through inactivation of Hypoxia-inducible factor (HIF)-1a. Cell cycle (Georgetown","volume":"19","author":"Bai","year":"2020","journal-title":"Tex)"},{"key":"10.1016\/j.biopha.2023.115125_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygcen.2017.02.017","article-title":"MiR-34a contributes to diabetes-related cochlear hair cell apoptosis via SIRT1\/HIF-1\u03b1 signaling","volume":"246","author":"Lin","year":"2017","journal-title":"Gen. Comp. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115125_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.115125_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"18","key":"10.1016\/j.biopha.2023.115125_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","article-title":"Dapagliflozin: a review of its use in patients with type 2 diabetes","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.115125_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbrc.2022.05.022","article-title":"Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1\/PGC-1\u03b1 pathway in obese mice","volume":"615","author":"He","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2023.115125_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/1440-1681.13638","article-title":"Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK\/SIRT1 activation","volume":"49","author":"Faridvand","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.biopha.2023.115125_bib23","first-page":"9","article-title":"DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure","author":"Kaplinsky","year":"2020","journal-title":"Drugs Context"},{"issue":"9","key":"10.1016\/j.biopha.2023.115125_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"issue":"8","key":"10.1016\/j.biopha.2023.115125_bib25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/jcmm.13076","article-title":"CD38 promotes angiotensin II-induced cardiac hypertrophy","volume":"21","author":"Guan","year":"2017","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF\u03b21\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2023.115125_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730623","article-title":"Dapagliflozin Mediates Plin5\/PPAR\u03b1 Signaling Axis to Attenuate Cardiac Hypertrophy","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115125_bib28","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/emboj\/18.7.1905","article-title":"Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP\/p300. The","volume":"18","author":"Ema","year":"1999","journal-title":"EMBO J."},{"issue":"49","key":"10.1016\/j.biopha.2023.115125_bib29","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/onc.2011.187","article-title":"C\/EBP-\u03b4 regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1\u03b1","volume":"30","author":"Min","year":"2011","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.biopha.2023.115125_bib30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41388-018-0552-1","article-title":"Bclaf1 promotes angiogenesis by regulating HIF-1\u03b1 transcription in hepatocellular carcinoma","volume":"38","author":"Wen","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2023.115125_bib31","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3389\/fphar.2020.01193","article-title":"Basic Fibroblast Growth Factor Attenuates Injury in Myocardial Infarction by Enhancing Hypoxia-Inducible Factor-1 Alpha Accumulation","volume":"11","author":"Rao","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib32","doi-asserted-by":"crossref","first-page":"15836","DOI":"10.1038\/s41598-021-95110-7","article-title":"Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1\u03b1\/VEGF signalling pathway","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115125_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/cvr\/cvz064","article-title":"Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1\u03b1-TAK1 signalling pathway","volume":"116","author":"Yan","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.115125_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2018.10.010","article-title":"Apigenin-induced HIF-1\u03b1 inhibitory effect improves abnormal glucolipid metabolism in Ang\u2161\/hypoxia-stimulated or HIF-1\u03b1-overexpressed H9c2 cells","volume":"62","author":"Zhu","year":"2019","journal-title":"Phytomedicine: Int. J. Phytother. Phytopharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:39:51Z","timestamp":1777880391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223009162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S0753332223009162"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115125","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1\/HIF-1\u03b1 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115125"}}